Neurogene
NGNE· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -9.9% in FY2025
Rachel McMinn is the CEO of Neurogene and was paid $3.2M in FY2025 (Dec), down 7%.
Pay$100 in the stock at the end of FY21 → $21
Executives3
See all- 1Rachel McMinnFounder and Chief Executive OfficerFY2025
- 2Christine MikailPresident and Chief Financial OfficerFY2025
- 3Julie JordanChief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allNeurogene paid its 3 named executives $7.4M in total in FY2025 (Dec). CEO Rachel McMinn was paid $3.2M of that.
| Name | |||
|---|---|---|---|
| Rachel McMinnFounder and Chief Executive Officer | |||
| Christine MikailPresident and Chief Financial Officer | |||
| Julie JordanChief Medical Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Neurogene. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Sarah B. Noonberg, M.D., Ph.D.Director · 6 yr on the boardIndependentCompensation—Paid as an executive
- Robert Baffi, Ph.D.Director · 2 yr on the boardIndependentCompensation, Nominating and Corporate Governance (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 16, 2026 | FY2025 |
| Annual report | 10-K | Mar 24, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 24, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 18, 2024 | FY2023 |
